secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001493152-22-031673
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera Q3 rev flat at $4.3M, net loss narrows; guides 2022 rev growth 24-31%
--------------------------------------------------------------------------------

- Q3 revenue $4.3M (flat YoY); net loss $2.6M ($0.11/shr) vs $16.0M loss in Q3 2021.
- 9-month revenue $18.5M (+24% YoY); net income $2.1M ($0.11 diluted) vs $23.2M loss in 9M 2021.
- Cash $27.5M (Sep 30, 2022) vs $24.5M (Dec 31, 2021); raised $4.3M net from warrant exercises and private placement.
- FY 2022 revenue guidance revised to 24-31% growth over 2021, citing seasonal strength in Q1 and Q4.
- Named Fred Leffler as CFO and Gerard DiGirolamo as National Sales Director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315222031673/0001493152-22-031673-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315222031673/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-031673

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer